

Amendments to the Claims:

The following is a complete list of claims indicating the changes incorporated by the present amendment and replacing all prior versions of the claims. Any claims canceled herein and all deletions made in claims that are not canceled herein are done so without prejudice to being re-instituted at a later date in this or a related application.


Listing of Claims:

1-69. (Canceled)

70. (Currently amended) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of any one of Claims 118 and claim 119.

71-118. (Canceled)

119. (Currently Amended) A compound having a formula (I):



and their pharmaceutically acceptable salts, wherein

R¹ is a member selected from the group consisting of phenyl aryl and heteroaryl;

P¹ is a primary pharmacophore selected from the group consisting of —

NHC(O)NH—, -OC(O)NH—, —NHC(O)O—, —CH₂C(O)NH—, —C(O)NH— and —NHC(O)—;

P² is a secondary pharmacophore selected from the group consisting of —C(O)—, —CH(OH)—, —O(CH₂CH₂O)_q—, —C(O)O—, —OC(O)—, —NHC(O)NH—, —OC(O)NH—, —NHC(O)O—, —C(O)NH— and —NHC(O)—;

P³ is a tertiary pharmacophore selected from the group consisting of C₂-C₆ alkynyl, C₁-C₆ haloalkyl, aryl, heteroaryl, —C(O)NHR¹, —C(O)NHS(O)₂R¹, —NHS(O)₂R²,

Amdt. dated June 12, 2008

Amendment under 37 CFR 1.116 Expedited Procedure

Examining Group 1654

-C(O)OR² and carboxylic acid analogs, wherein R² is a member selected from the group consisting of hydrogen, unsubstituted C₁-C₄ alkyl, substituted C₁-C₄ alkyl, unsubstituted C₃-C₈ cycloalkyl, substituted C₃-C₈ cycloalkyl, unsubstituted aryl, substituted aryl, unsubstituted aryl C₁-C₄ alkyl, and substituted aryl C₁-C₄ alkyl;

the subscripts n and m are each independently 0 or 1, and at least one of n or m is 1, and the subscript q is 0 to 3;

L¹ is a first linker selected from the group consisting of unsubstituted C₂-C₆ alkylene, substituted C₂-C₆ alkylene, unsubstituted C₃-C₆ cycloalkylene, substituted C₃-C₆ cycloalkylene, unsubstituted arylene, substituted arylene, unsubstituted heteroarylene, and substituted heteroarylene; and

L² is a second linker selected from the group consisting of unsubstituted C₂-C₁₂ alkylene, substituted C₂-C₁₂ alkylene, unsubstituted arylene, substituted arylene, and combinations thereof.

120. (Currently Amended) The compound according to any one of Claims 118 and claim 119, wherein P³ is -C(O)OR² or a carboxylic acid analog, wherein R² is selected from the group consisting of hydrogen, unsubstituted C₁-C₄ alkyl, substituted C₁-C₄ alkyl, unsubstituted C₃-C₈ cycloalkyl, and substituted C₃-C₈ cycloalkyl.

121. (Currently Amended) The compound according to any one of Claims 118 and claim 119, wherein P³ is -C(O)OR² or a carboxylic acid analog, wherein R² is selected from the group consisting of hydrogen, methyl, and ethyl.

122. (Canceled)

123. (Withdrawn) The compound of Claim 119, wherein R¹ is phenyl.

124. (Withdrawn) The compound of Claim 119, wherein R¹ is phenyl, wherein the phenyl is either unsubstituted or substituted with from one to three substituents selected from the group consisting of halogen, lower alkyl, lower halo alkyl, lower alkoxy, C₃-C₅ cycloalkyl, and cyano.

125. (Previously Presented) The compound of Claim 119, wherein P¹ is selected from the group consisting of -NHC(O)CH-, -OC(O)NH-, and -NHC(O)O-.

126. (Previously Presented) The compound of Claim 119, wherein P¹ is -NHC(O)CH-.

127. (Previously Presented) The compound of Claim 119, wherein L¹ is an alkylene of from 2 to 4 carbon atoms,

P² is not present; and

L² is an alkylene of from 2 to 8 carbon atoms.

128. (Previously Presented) The compound of Claim 119, wherein P¹ is selected from the group consisting of —NHC(O)NH—, -OC(O)NH— and —NHC(O)O—;

n is 0;


m is 1;






L¹ is selected from the group consisting of unsubstituted C₂-C₆ alkylene, unsubstituted C₃-C₆cycloalkylene, substituted C₃-C₆cycloalkylene, unsubstituted arylene, and substituted arylene;


L² is selected from the group consisting of unsubstituted C₂-C₆ alkylene and substituted C₂-C₆ alkylene; and








P³ is selected from the group consisting of C₂-C₆ alkynyl, C₁-C₆ haloalkyl, aryl, heteroaryl, —C(O)NHR², —C(O)NHS(O)₂R², —NHS(O)₂R², —C(O)OR², and carboxylic acid analogs, wherein R² is a member selected from the group consisting of hydrogen, unsubstituted C₁-C₄ alkyl, substituted C₁-C₄ alkyl, unsubstituted C₃-C₈ cycloalkyl, substituted C₃-C₈ cycloalkyl, unsubstituted aryl, substituted aryl, unsubstituted aryl C₁-C₄ alkyl, and substituted aryl C₁-C₄ alkyl.


129. (Currently Amended) A compound having the formula selected from the group consisting of:





























wherein Z is O or NH ;

R^3 is alkyl;

$n1$ is 1, 2, 3, 4, 6, 7, 9, 10, or 11;


$n2$ is 1, 2, 3, or 4;

$n3$ is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

and their pharmaceutically acceptable salts.

130. (Canceled)

131. (Currently Amended) A compound having a formula



and their pharmaceutically acceptable salts, wherein

P^3 is selected from the group consisting of C_2 - C_6 alkynyl, C_1 - C_6 haloalkyl, aryl, heteroaryl, $-NHS(O)_2R^2$, $-C(O)OR^2$ and carboxylic acid analogs, wherein R^2 is a member selected from the group consisting of hydrogen, unsubstituted C_1 - C_4 alkyl, substituted C_1 - C_4 alkyl, unsubstituted C_3 - C_8 cycloalkyl, substituted C_3 - C_8 cycloalkyl, unsubstituted aryl, substituted aryl, unsubstituted aryl C_1 - C_4 alkyl, and substituted aryl C_1 - C_4 alkyl;

the subscript m is 1;

L¹ is unsubstituted C₃-C₄ alkylene or substituted C₃-C₄ alkylene;

L² is unsubstituted C₈ alkylene or substituted C₈ alkylene.

132. (Previously Presented) A compound having the formula:

